This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The study compared maintenance therapy (pemetrexed in combination with best supportive care) with best supportive care alone.
Location/setting
Switzerland/In-patient secondary care.
Methods

Analytical approach:
A Markov model was constructed to assess the costs and outcomes of the two interventions under study. The time horizon of the study was the lifetime of the patient. The perspective adopted in the economic analysis was that of the Swiss healthcare system.
Effectiveness data:
The clinical and effectiveness data were derived from a single phase III placebo-controlled randomised study by Ciuleanu et al. (see Other Publications of Related Interest). The main measure of effectiveness used in the model was progression-free survival. Overall survival was considered as a secondary outcome. The authors reported that progression-free survival was only estimated from the 481 non-squamous cell lung cancer patients included in the trial. Hazards were assumed constant over time and were converted into transition probabilities using median time spent in each stage of disease.
Monetary benefit and utility valuations:
Utility estimates were derived from previously published studies.
Measure of benefit:
Quality-adjusted life-years (QALYs) gained. Benefits could be generated over the lifetime of the patient. The short life expectancy of patients meant that benefits were left undiscounted.
Cost data:
The direct costs included in the economic analysis were pemetrexed, chemotherapy, monitoring, treatment of side-
